Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 6 h8 y. F5 {) c7 I' V: `, w) v
5 e, R; U- q0 I2 C) M R
. C# _2 M* {( U( |9 Q0 G; @6 SSub-category:! R: q& w. f9 |( o" B, n J, t
Molecular Targets ( `: a; l- g$ O& g" {# O8 b* B8 t
+ B6 \1 F( U8 U+ P" {* [
d& n3 g& D# V! _
Category:
6 {' C0 @! I. I/ g9 `Tumor Biology : x0 [) H& u% `, y+ d/ k
; X$ k S0 @5 o$ v* _* X4 g, Q2 |1 Z
; k/ t- N7 n1 Z5 T/ D* X
Meeting:# h: j. T: P, `) K6 }
2011 ASCO Annual Meeting
1 q; D' E h! r
7 ~: r0 J% N f8 P" J* ~& d4 G
9 Z9 O7 Q! b6 F; G/ M8 U- k8 lSession Type and Session Title:5 ^7 O2 K( L* l( Y% e3 ?7 c
Poster Discussion Session, Tumor Biology 9 M$ R( |5 A6 a
* L/ t. Q/ _. j; y2 h' @8 c3 `
1 p3 G$ }- d0 }6 sAbstract No:
+ {( v B W ]. j& e1 \- A5 O10517
/ U! r9 p! @$ ~+ |) D$ Z" I3 B- O+ F' V7 ]3 k1 h
" j6 k$ o- e5 {7 R" p+ N
Citation:! ?) ]) W: n2 D
J Clin Oncol 29: 2011 (suppl; abstr 10517)
7 n( T' c# r, M+ O0 i; N8 `
! | x5 s3 m V5 X6 ]% g: \# V* _' ?; o
Author(s):
3 L6 g) a9 G, z& {7 M" yJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China : u3 Q1 h( b, J4 k( }) b1 b7 W
, {# y: o" w" A/ X3 [: K o
" E$ Q. {) W3 J% \/ J! P- X; l8 e+ ]* B; {
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
4 ]$ Y/ z: @& d; d# ~, M% ]9 U( i& O& s9 H
Abstract Disclosures
0 `' V$ Y$ {9 G, @7 |5 {, J7 N# Y6 N5 c7 Q- a' K# f1 N0 a
Abstract:
7 D" x! m+ w) @9 D, `
5 V5 I, T0 e6 Y0 j4 X/ V/ l n. j
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation." x; {) a8 a, ~9 I* }9 d
7 d( `* Q( s7 \# W: y- Q
5 H" L$ A' V0 J- n |